ReviewAnnals of gastroenterological surgery2026
Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review.
Review in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Carbohydrate antigen 72-4 and tumor-associated glycoprotein 72 - tumor marker: Past, present and future.World journal of gastrointestinal pathophysiology · 2026Review
- Masseter muscle change during chemoradiotherapy for esophageal cancer: survival and immunonutritional associations compared with the psoas muscle index.Surgery today · 2026Article
- DDR1 in esophageal squamous cell carcinoma: bioinformatics discovery and experimental validation.Translational cancer research · 2026Article
- Early increase of CD103 expression on peripheral PD-1Cancer immunology, immunotherapy : CII · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Serum tumor markers are helpful for diagnosis, monitoring treatment outcomes, and prognosis. However, their clinical utility for esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC) remains unclear. This study aimed to comprehensively evaluate recent studies on serum tumor markers in ESCC and GC. Methods: We conducted a systematic review and meta-analysis of studies published between January 2010 and March 2025 using PubMed. Overall, 84 and 468 articles on ESCC and GC were extracted, respectively. The sensitivity, specificity, positive predictive value, and summary receiver operating characteristic curves were calculated and evaluated using a systematic review and meta-analysis. Prognostic values were assessed using the hazard ratio based on univariate and multivariate analyses. Results: In ESCC, squamous cell carcinoma antigen (SCC-Ag) exhibited the highest sensitivity (38.7%) and positive predictive value (85.2%); moreover, it was the only independent prognostic factor across multiple articles. Carcinoembryonic antigen (CEA) and cytokeratin 19 fragment had low sensitivity and predictive value, whereas serum p53 antibody demonstrated moderate prognostic relevance. In GC, CEA and CA125 had the highest sensitivity (37.2%) and positive predictive value (72.2%), respectively, and CA125 and CA72-4 were associated with peritoneal dissemination. CEA and CA125 levels were independent prognostic markers of GC. Conclusion: SCC-Ag is a key marker for ESCC diagnosis and prognosis. CEA and CA125 are valuable markers for GC prognosis, whereas CA125 and CA72-4 help detect peritoneal dissemination. Further research integrating the molecular characteristics of each tumor marker is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.